Literature DB >> 27473736

Overview of Thoracic Oncology Trials in Cooperative Groups Around the Globe.

Ameen Abdulla Salahudeen1, Manali I Patel1, Paul Baas2, Walter J Curran3, Jeffrey D Bradley4, David R Gandara5, Glenwood D Goss6, Tony S Mok7, Suresh S Ramalingam1, Everett E Vokes8, Shakun M Malik9, Heather A Wakelee10.   

Abstract

Survival rates of patients with either early and advanced stage non-small-cell lung cancer (NSCLC) have improved with newer systemic therapy and radiation techniques, including combination regimens, targeted therapies, and immunotherapies. The cancer cooperative groups have historically played a critical role in the advancement of NSCLC therapy. Annually, representatives from cooperative groups worldwide convene at the International Lung Cancer Congress (ILCC). In summer 2015, the ILCC reached its 16th anniversary. This article highlights the NSCLC studies presented by participating groups in 2015.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cooperative group; Mesothelioma; NCTN; NSCLC; SCLC

Mesh：

Year:  2016        PMID： 27473736      PMCID： PMC5361177          DOI： 10.1016/j.cllc.2016.06.007

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN： 1525-7304            Impact factor:   4.785


  15 in total

Review 1.  50 Years of progress in the systemic therapy of non-small cell lung cancer.

Authors:  Heather Wakelee; Karen Kelly; Martin J Edelman
Journal:  Am Soc Clin Oncol Educ Book       Date:  2014

Review 2.  Non-Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy.

Authors:  David P Carbone; David R Gandara; Scott J Antonia; Christoph Zielinski; Luis Paz-Ares
Journal:  J Thorac Oncol       Date:  2015-07       Impact factor: 15.609

3.  Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study-CALGB 30504 (Alliance).

Authors:  Neal E Ready; Herbert H Pang; Lin Gu; Gregory A Otterson; Sachdev P Thomas; Antonius A Miller; Maria Baggstrom; Gregory A Masters; Stephen L Graziano; Jeffrey Crawford; Jeffrey Bogart; Everett E Vokes
Journal:  J Clin Oncol       Date:  2015-03-02       Impact factor: 44.544

4.  Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial.

Authors:  Li Zhang; Shenglin Ma; Xiangqun Song; Baohui Han; Ying Cheng; Cheng Huang; Shujun Yang; Xiaoqing Liu; Yunpeng Liu; Shun Lu; Jie Wang; Shucai Zhang; Caicun Zhou; Xiangwei Zhang; Nobuya Hayashi; Mengzhao Wang
Journal:  Lancet Oncol       Date:  2012-04-17       Impact factor: 41.316

5.  Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04.

Authors:  Jin Seok Ahn; Yong Chan Ahn; Joo-Hang Kim; Chang Geol Lee; Eun Kyung Cho; Kyu Chan Lee; Ming Chen; Dong-Wan Kim; Hoon-Kyo Kim; Young Joo Min; Jin-Hyoung Kang; Jin-Hyuck Choi; Sang-We Kim; Guangying Zhu; Yi-Long Wu; Sung Rok Kim; Kyung Hee Lee; Hong Suk Song; Yoon-La Choi; Jong-Mu Sun; Sin-Ho Jung; Myung-Ju Ahn; Keunchil Park
Journal:  J Clin Oncol       Date:  2015-07-06       Impact factor: 44.544

6.  Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.

Authors:  Takashi Seto; Terufumi Kato; Makoto Nishio; Koichi Goto; Shinji Atagi; Yukio Hosomi; Noboru Yamamoto; Toyoaki Hida; Makoto Maemondo; Kazuhiko Nakagawa; Seisuke Nagase; Isamu Okamoto; Takeharu Yamanaka; Kosei Tajima; Ryosuke Harada; Masahiro Fukuoka; Nobuyuki Yamamoto
Journal:  Lancet Oncol       Date:  2014-08-27       Impact factor: 41.316

Review 7.  Review of the current targeted therapies for non-small-cell lung cancer.

Authors:  Kim-Son H Nguyen; Joel W Neal; Heather Wakelee
Journal:  World J Clin Oncol       Date:  2014-10-10

8.  Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project.

Authors:  Fiona H Blackhall; Solange Peters; Lukas Bubendorf; Urania Dafni; Keith M Kerr; Henrik Hager; Alex Soltermann; Kenneth J O'Byrne; Christoph Dooms; Aleksandra Sejda; Javier Hernández-Losa; Antonio Marchetti; Spasenija Savic; Qiang Tan; Erik Thunnissen; Ernst-Jan M Speel; Richard Cheney; Daisuke Nonaka; Jeroen de Jong; Miguel Martorell; Igor Letovanec; Rafael Rosell; Rolf A Stahel
Journal:  J Clin Oncol       Date:  2014-07-28       Impact factor: 44.544

9.  Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.

Authors:  Yi-Long Wu; Jin Soo Lee; Sumitra Thongprasert; Chong-Jen Yu; Li Zhang; Guia Ladrera; Vichien Srimuninnimit; Virote Sriuranpong; Jennifer Sandoval-Tan; Yunzhong Zhu; Meilin Liao; Caicun Zhou; Hongming Pan; Victor Lee; Yuh-Min Chen; Yan Sun; Benjamin Margono; Fatima Fuerte; Gee-Chen Chang; Kasan Seetalarom; Jie Wang; Ashley Cheng; Elisna Syahruddin; Xiaoping Qian; James Ho; Johan Kurnianda; Hsingjin Eugene Liu; Kate Jin; Matt Truman; Ilze Bara; Tony Mok
Journal:  Lancet Oncol       Date:  2013-06-17       Impact factor: 41.316

10.  Assessing standardization of molecular testing for non-small-cell lung cancer: results of a worldwide external quality assessment (EQA) scheme for EGFR mutation testing.

Authors:  S Patton; N Normanno; F Blackhall; S Murray; K M Kerr; M Dietel; M Filipits; S Benlloch; S Popat; R Stahel; E Thunnissen
Journal:  Br J Cancer       Date:  2014-07-01       Impact factor: 7.640
View more
  1 in total

1.  Better Together: The Making and Maturation of the Palliative Care Research Cooperative Group.

Authors:  Christine L Ritchie; Kathryn I Pollak; Karen A Kehl; Jeri L Miller; Jean S Kutner
Journal:  J Palliat Med       Date:  2017-04-27       Impact factor: 2.947
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.